Lentiviral vector and method to pre-select/sort anti-HIV gene transduced cells prior to clinical transplantation.
Current HIV gene protocols including stem cell gene therapy have not demonstrated any efficacy in clinical trials due to low transduction efficiencies and low in vivo gene marking. Currently used marking methods include the use of EGFP, which is used as a reporter gene to track transduced cells or to sort cells by flow cytometry. EGFP is not a natural protein and can be recognized as a foreign antigen and transduced cells get rejected.
Researchers at the University of California, Davis have developed a novel anti-HIV lentivirus vector that expresses a selective cell surface marker to purify the transduced cells. Expression of this selective marker on the surface of the transduced hematopoietic stem cells gives these cells a unique cell surface signature which could be used to distinguish them from non-transduced cells. This selective marker is not found on the surface of CD34+ HSCs. Therefore, for HIV stem cell gene therapy these vectors can be used to pre-select or sort the anti-HIV gene transduced cells prior to clinical transplantation. The transduced cells can be purified by immunomagnetic bead separation to obtain a pure or enriched population of anti-HIV transfected cells.
Country | Type | Number | Dated | Case |
United States Of America | Published Application | 20220347316 | 11/03/2022 | 2011-758 |
United States Of America | Published Application | 20150283266 | 10/08/2015 | 2011-758 |
Gene therapy, HIV, In vivo transduction, Vector, Cell therapy, Ex vivo, Pre-Selection Marker, Hematopoetic Stem Cells, Transplantation